The added value of right ventricular function normalized for afterload to improve risk stratification of patients with pulmonary arterial hypertension.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
07
2021
accepted:
22
02
2022
entrez:
19
5
2022
pubmed:
20
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
Risk stratification is central to the management of pulmonary arterial hypertension (PAH). For this purpose, multiparametric tools have been developed, including the ESC/ERS risk score and its simplified versions derived from large database analysis such as the COMPERA and the French Pulmonary Hypertension Network (FPHN) registries. However, the distinction between high and intermediate-risk profiles may be difficult as the latter lacks granularity. In addition, neither COMPERA or FPHN strategies included imaging-derived markers. We thus aimed at investigating whether surrogate echocardiographic markers of right ventricular (RV) to pulmonary artery (PA) coupling could improve risk stratification in patients at intermediate-risk. A single-center retrospective analysis including 102 patients with a diagnosis of PAH was performed. COMPERA and FPHN strategies were applied to stratify clinical risk. The univariate linear regression was used to test the influence of the echo-derived parameters qualifying the right heart (right ventricle basal diameter, right atrial area, and pressure, tricuspid regurgitation velocity, tricuspid annular plane systolic excursion -TAPSE-). Among these, the TAPSE and tricuspid regurgitation velocity ratio (TAPSE/TRV) as well as the TAPSE and systolic pulmonary artery pressure ratio (TAPSE/sPAP) were considered as surrogate of RV-PA coupling. TAPSE/TRV and TAPSE/sPAP resulted the more powerful markers of prognosis. Once added to COMPERA, TAPSE/TRV or TAPSE/sPAP significantly dichotomized intermediate-risk group in intermediate-to-low-risk (TAPSE/TRV≥3.74 mm∙nm/s)-1 or TAPSE/sPAP≥0.24 mm/mmHg) and in intermediate-to-high-risk subgroups (TAPSE/TRV<3.74 mm∙(m/s)-1 or TAPSE/sPAP<0.24 mm/mmHg). In the same way, TAPSE/TRV or TAPSE/sPAP was able to select patients at lower risk among those with 2, 1, and 0 low-risk criteria of both invasive and non-invasive FPHN registries. Our results suggest that adopting functional-hemodynamic echo-derived parameters may provide a more accurate risk stratification in patients with PAH. In particular, TAPSE/TRV or TAPSE/sPAP improved risk stratification in patients at intermediate-risk, that otherwise would have remained less characterized.
Sections du résumé
BACKGROUND
Risk stratification is central to the management of pulmonary arterial hypertension (PAH). For this purpose, multiparametric tools have been developed, including the ESC/ERS risk score and its simplified versions derived from large database analysis such as the COMPERA and the French Pulmonary Hypertension Network (FPHN) registries. However, the distinction between high and intermediate-risk profiles may be difficult as the latter lacks granularity. In addition, neither COMPERA or FPHN strategies included imaging-derived markers. We thus aimed at investigating whether surrogate echocardiographic markers of right ventricular (RV) to pulmonary artery (PA) coupling could improve risk stratification in patients at intermediate-risk.
MATERIAL AND METHODS
A single-center retrospective analysis including 102 patients with a diagnosis of PAH was performed. COMPERA and FPHN strategies were applied to stratify clinical risk. The univariate linear regression was used to test the influence of the echo-derived parameters qualifying the right heart (right ventricle basal diameter, right atrial area, and pressure, tricuspid regurgitation velocity, tricuspid annular plane systolic excursion -TAPSE-). Among these, the TAPSE and tricuspid regurgitation velocity ratio (TAPSE/TRV) as well as the TAPSE and systolic pulmonary artery pressure ratio (TAPSE/sPAP) were considered as surrogate of RV-PA coupling.
RESULTS
TAPSE/TRV and TAPSE/sPAP resulted the more powerful markers of prognosis. Once added to COMPERA, TAPSE/TRV or TAPSE/sPAP significantly dichotomized intermediate-risk group in intermediate-to-low-risk (TAPSE/TRV≥3.74 mm∙nm/s)-1 or TAPSE/sPAP≥0.24 mm/mmHg) and in intermediate-to-high-risk subgroups (TAPSE/TRV<3.74 mm∙(m/s)-1 or TAPSE/sPAP<0.24 mm/mmHg). In the same way, TAPSE/TRV or TAPSE/sPAP was able to select patients at lower risk among those with 2, 1, and 0 low-risk criteria of both invasive and non-invasive FPHN registries.
CONCLUSIONS
Our results suggest that adopting functional-hemodynamic echo-derived parameters may provide a more accurate risk stratification in patients with PAH. In particular, TAPSE/TRV or TAPSE/sPAP improved risk stratification in patients at intermediate-risk, that otherwise would have remained less characterized.
Identifiants
pubmed: 35587927
doi: 10.1371/journal.pone.0265059
pii: PONE-D-21-22876
pmc: PMC9119555
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0265059Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Cardiol. 2010 Apr 30;140(3):272-8
pubmed: 19070379
Chest. 2015 Apr;147(4):1063-1071
pubmed: 25376008
Eur Respir J. 2019 Nov 21;54(5):
pubmed: 31515402
Eur Respir Rev. 2014 Dec;23(134):476-87
pubmed: 25445946
Circulation. 2009 Sep 15;120(11):992-1007
pubmed: 19752350
Pulm Circ. 2020 Oct 7;10(4):2045894020961739
pubmed: 33088480
Am J Manag Care. 2019 Mar;25(3 Suppl):S47-S52
pubmed: 31002488
Circulation. 2016 Jun 14;133(24):2413-22
pubmed: 27169739
Am J Respir Crit Care Med. 2009 Apr 1;179(7):615-21
pubmed: 19164700
Eur Respir J. 2017 Aug 3;50(2):
pubmed: 28775050
Int J Cardiol. 2018 Sep 1;266:229-235
pubmed: 29887454
J Am Soc Echocardiogr. 2006 Jul;19(7):902-10
pubmed: 16825000
J Heart Lung Transplant. 2017 Jul;36(7):754-762
pubmed: 28131663
Can Med Assoc J. 1985 Apr 15;132(8):919-23
pubmed: 3978515
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Circulation. 2018 Feb 13;137(7):693-704
pubmed: 29070502
Pulm Circ. 2017 Apr-Jun;7(2):361-371
pubmed: 28597759
Eur Heart J. 2018 Dec 14;39(47):4175-4181
pubmed: 28575277
Eur Respir J. 2020 Sep 24;56(3):
pubmed: 32430422
Int J Cardiol. 2016 Jan 1;202:736-40
pubmed: 26469553
Lung. 2018 Apr;196(2):157-164
pubmed: 29435740
Eur J Heart Fail. 2019 Feb;21(2):137-155
pubmed: 30600580
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Chest. 2011 May;139(5):988-993
pubmed: 20864617
Eur Respir J. 2017 Aug 3;50(2):
pubmed: 28775047
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545976
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545974
Pulm Circ. 2022 Jan 12;12(1):e12026
pubmed: 35506081
Chest. 2015 Oct;148(4):1043-54
pubmed: 26066077
Eur Respir Rev. 2011 Dec;20(122):243-53
pubmed: 22130817
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545971
Am J Respir Crit Care Med. 2006 Nov 1;174(9):1034-41
pubmed: 16888289
Eur Respir Rev. 2012 Mar 1;21(123):8-18
pubmed: 22379169